Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-06-18

The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all-cause mortality in acute myocardial infarction

Cel

Although the long term prognosis of patients suffering acute myocardial infarction (AMI) has improved since the introduction of reperfusion therapies and primary angioplasty, the 1 year mortality of patients with AMI and resultant left ventricular systolic dysfunction (LVSD) is still as high as 13%. A major reason for the high morbidity and mortality is that the heart has an inadequate regenerative response to the myocardial necrosis sustained following AMI; cell death from the ischaemic damage can lead to progressive ventricular dilation and dysfunction through the processes of vascular remodelling. Despite the use of full conventional treatment, including ACE inhibitors, beta-blockers, aldosterone inhibitors and diuretics, yearly mortality rates of patients with post-infarction heart failure are still in the range of 13 % and rehospitalisation for worsening of heart failure occurs at a yearly rate of 6–8%.

Clinical data now exists supporting the concept that autologous bone marrow derived cells can restore cardiac function following AMI. We plan to advance this research in the BAMI project and will:
• Develop a standardised method of bone marrow cell collection
• Develop a standardised method of optimising reparative potential of bone marrow derived cells
• Standardise bone marrow preparation procedure so that it can be universally applied
• Standardise method of bone marrow cell delivery post AMI
• Conduct the first large scale all-cause mortality clinical trial to test if the product and delivery method mentioned above can lead to a 25% reduction in mortality end-point at 2 years

Our project will establish the therapeutic value of this approach to stem cell therapy. Success will demonstrate that transcoronary infusion of bone marrow-derived progenitor cells is safe and will reduce the mortality rate by 25% and reduce the rehospitalisation rate by 15%.

Dziedzina nauki

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

FP7-HEALTH-2011-two-stage
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

CP-FP - Small or medium-scale focused research project

Koordynator

QUEEN MARY UNIVERSITY OF LONDON
Wkład UE
€ 1 979 853,55
Adres
327 MILE END ROAD
E1 4NS London
Zjednoczone Królestwo

Zobacz na mapie
Region
London Inner London — East Tower Hamlets
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Dylbere Koteci (Mrs.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (21)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 25 Maja 2022

Moja broszura

Permalink: https://cordis.europa.eu/project/id/278967/pl

European Union, 2024